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Background: Spontaneous canine mammary tumors constitute a serious clinical problem. There are significant
differences in survival between cases with different tumor grades. Unfortunately, the distinction between various
grades is not clear. A major problem in evaluating canine mammary cancer is identifying those, that are “truly”
malignant. That is why the aim of our study was to find the new markers of canine malignancy, which could help
to diagnose the most malignant tumors.
Results: Analysis of gene expression profiles of canine mammary carcinoma of various grade of malignancy
followed by the boosted tree analysis distinguished a `gene set`. The expression of this gene set (sehrl, zfp37, mipep,
relaxin, and magi3) differs significantly in the most malignant tumors at mRNA level as well as at protein level.
Despite this `gene set` is very interesting as an additional tool to estimate canine mammary malignancy, it should
be validated using higher number of samples.
Conclusions: The proposed gene set can constitute a `malignancy marker` that could help to distinguish the most
malignant canine mammary carcinomas. These genes are also interesting as targets for further investigations and
therapy. So far, only two of them were linked with the cancer development.
Keywords: Canine mammary malignancy, Malignancy classifier, sehrl, mipep, magi3, zfp37, RelaxinBackground
Spontaneous mammary tumors are the most common
type of cancer in women and in female dogs. The annual
incidence in dogs is 3 times more frequent than in
humans. Thus, it constitutes a serious clinical problem
[1]. Unfortunately, the distinction between various
grades of tumors can be considerably less clear than one
would like [2]. A major problem in evaluating canine
mammary cancer is identifying those, that are “truly”
malignant [3]. The most significant criteria for the diag-
nosis of malignant mammary tumors in the dog are as
follow: tumor type, significant nuclear and cellular pleo-
morphism, mitotic index, presence of randomly distrib-
uted areas of necrosis within the neoplasm, peritumoral
and lymphatic invasion, and regional lymph node metas-
tasis. However, classification based on these criteria* Correspondence: magdalena_krol@sggw.pl
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distribution, and reproduction in any mediumsometimes leads to the over-diagnosis of mammary car-
cinoma [3]. However, good pathological diagnosis consti-
tute basis to yet proper prognosis [1]. Karayannopoulou
et al. [4] found significant differences in survival between
cases with different tumor grades: survival was worse in
dogs with grade III carcinomas than in those with grade
I or grade II.
The advent of DNA microarrays - a modern and power-
ful tool for investigation of biological processes through
the widespread analysis of genes from a particular cell, tis-
sue, or organism - enabled investigators to identify charac-
teristic expression patterns of groups of genes that are
associated with specific tumor traits. They are a great hope
of finding new cancer markers, markers of clinical out-
come, and targets for anticancer therapy [5].
The purpose of this preliminary study was to point out
find new markers of canine mammary malignancy (that
could help to improve pathological diagnosis of the
tumor grade) based on the gene expression. We built
the molecular classifier, which was able to distinguish
the most malignant canine mammary tumors from thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Pawłowski et al. BMC Veterinary Research 2013, 9:138 Page 2 of 9
http://www.biomedcentral.com/1746-6148/9/138lowest estimated malignant tumors. As of the highest
grade of malignancy is associated with an increased risk
of death within 2 years after mastectomy [4], proper
diagnosis may lead to prediction to the clinical outcome.
Methods
Tissue samples
Tumor samples of canine mammary cancers were
obtained from patients subjected to surgery. The tumors
then, were divided into two halves, one of them was
fixed in 10% neutral buffered formalin and routinely em-
bedded in paraffin to perform histological assay (n = 78
samples in total). Whereas the other one was snap fro-
zen in liquid nitrogen and stored in −80°C (n = 18).
Four μm samples from paraffin blocks were fixed on
glass slides, stained with haematoxylin – eosin (HE) and
had been examined by certified pathologists (prof.
Dr. hab. Elżbieta Malicka and Dr. Izabella Dolka, both
from the Warsaw University of Life Sciences, Poland).
The immunohistochemical examination of cytokeratin,
vimentin, smooth muscle actin, s100 protein and p63
protein expression was performed in order to diagnose
these tumors (data not shown). The tumor types of spec-
imens were classified based on the World Health
Organization (WHO) Histological Classification and
Mammary Tumors of the Dog and Cat classification [6].
Histological tumor grading was conducted on HE-
stained sections using a Misdorp classification [6]. The
mammary carcinoma grading was assessed in respect to
tubule formation, degree of differentiation and mitotic
index as grade I, grade II, or grade III tumor. The tu-
mors dedicated to this study were non-metastatic (no
metastasis detected in lymph nodes or lungs of the pa-
tients). Clinical information about the outcome of these
patients is unknown.
Statistical analysis and building of the classifier of canine
mammary malignancy
To create the molecular classifier of canine mammary
malignancy we used our previous data [1] deposited in
NCBI's Gene Expression Omnibus (GEO) with Series
accession number GSE 29601. Briefly, the statistical
analysis of gene expression was performed using linear
methods for microarrays (limma package in Bioconductor
software) [7]. The method tests the null hypothesis of no
differential expression between the groups of samples
compared was performed by using the moderated t-
statistic [7], which has similar interpretation as the ordin-
ary t-test statistic. The expression of genes with the
Benjamini-Hochberg (FDR) multiple-testing corrected
p-value below 0.05 was qualified as significantly changed.
Each of the microarrays had been examined separately.
Our previously conducted unsupervised analysis [1] had
classified the examined canine mammary tumor tissues(grade I, grade II and grade III) into three groups. For the
purposes of the hereby study we were mainly focused on
two of them: the 1st which consisted of 4 grade III and 1
grade II carcinomas (it was the most malignant group)
and the second consisted of 4 grade I carcinomas (it was
the group consisted of the lowest estimated malignant tu-
mors) (Figure 1A). We were focused only on these two
groups to find genes that present exact characteristic for
the most malignant tumors. Thus, to build a canine mam-
mary malignancy classifier the following training data were
used: the most malignant tumors (n = 8, two hybridiza-
tions per patient) and the lowest estimated malignant tu-
mors (n = 10, two hybridizations per patient).
We removed genes with low expression (arbitrary
threshold was used where genes with signal < 100 in
more than half of the samples tested were removed).
First, we identified 20 most differentially expressed genes
(Table 1, Figure 1B) between the groups of the most ma-
lignant and the lowest estimated malignant tumors in
the training data. Analysis of differentially expressed
genes was done based on the nonparametric Wilcoxon
test. These genes were used as features for training the
classifier of canine mammary the most malignant
tumors.
Prior to building the classifier we calculated expression
of the selected genes relative to the median expression
the reference genes as measured on the same microarray
(rps19, cgi-119, ctbp1 and b2m were used as the refer-
ence genes) [8,9]. We built the classifier using this rela-
tive signal calculated for features listed in Table 1. The
decision tree classifier was built with the use of boosted
C5.0 algorithm.
The gene function was identified with the use of NCBI
database and PANTHER pathway analysis software [9]. The
pathway analyses were conducted using one-way ANOVA
with binominal Bonferroni statistic test (PANTHER) with
the cut-off value p < 0.05.
Real-time qPCR
The mRNA sequences of the key genes were obtained
from NCBI database. Primers were designed with
the PRIMER3 software (free on-line access) and checked
using Oligo Calculator (free on-line access) and Primer-
Blast (NCBI database). Primers’ sequences are listed
in Table 2. hprt and rps19 genes were used as non-
regulated reference genes for normalization of target gene
expression [8,9]. For the analysis, n = 18 canine mammary
cancer samples were used (6 tumors of each grade). Quan-
titative RT-PCR was performed with the fluorogenic
Lightcycler Fast Strand DNA Syber Green (Roche) and
the Light Cycler (Roche). The results were analyzed based
on comparative Ct method [10]. Relative transcript abun-
dance of the gene equals ΔCt values (ΔCt = Ctreference –
Cttarget). Relative changes in transcript are expressed as
Figure 1 The clustering of tumors taken to the analysis and variation in expression of 20 the mostly significant genes between the
most and less malignant canine mammary tumors. A. Differences in expression of genes in 12 examined samples. Data is presented in a
matrix format: each row represents a single gene, and each column an experimental sample. In each sample, the ratio of the abundance of
transcripts of each gene to the median abundance of the gene's transcript across all tissue samples is represented by the color of the
corresponding cell in the matrix. Green squares, transcript levels below the median; red squares, transcript levels greater than the median. Color
saturation reflects the magnitude of the ratio relative to the median for each set of samples. B. Boxplots comparing relative signal measured for
20 most significantly changed genes between less malignant (yellow) and the most malignant (green) tumors.
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The experiment was conducted three times.
Immunohistochemistry
Four μm sections from paraffin blocks containing
tumour tissue (n = 60 in total; 20 tumor tissues from
each grade of malignancy) were baked in 37°C over-
night. After dewaxing in xylene and rehydration in etha-
nol, for antigen retrieval, the slides were placed in
0.02 M citrate buffer, pH 6.0 and boiled in the
decloaking chamber. The samples were incubated in the
Peroxidase Blocking Reagent (Dako, Denmark) for
10 min at room temperature prior to the antibody incu-
bation. After 30 min incubation in 5% bovine serum al-
bumin (Sigma Aldrich, Germany), the following mouse/
rabbit primary antibodies were used (diluted 1:100 in 1%
bovine serum): anti MAGI3, ZFP37, SERHL, Relaxin,
MIPEP (all of them obtained from Abcam, UK). The
slides were incubated with antibodies overnight at +4°C.For the staining the EnVision kit (Dako) was used
(Labelled Polymers consist of secondary anti-mouse or
anti-rabbit antibodies conjugated with the Horseradish
peroxidase HRP enzyme complex). To develop the col-
ored product, the 3,3`-Diaminobenzidine (DAB) sub-
strate was used. Finally, the haematoxylin was taken for
nuclei counterstaining. To confirm the differences in ex-
pression of these antigens between tumors of the various
grade, n = 60 samples per each antibody were examined.
For each immunohistochemical experiment the nega-
tive control was used (the staining without the use of
primary antibodies).Statistical analysis
The statistical analysis of Real-time qPCR and immuno-
histochemistry was conducted using Prism version
5.00 software (GraphPad Software, USA). The one-way
ANOVA, and ANOVA + Tukey HSD (Honestly Significant























Twenty genes that were significantly changed in grade III tumors. This gene
set was selected based on the calculation of the gene expression of all the
spots from all microarrays (n = 36) versus median expression of the reference
genes for canine mammary cancer [7,8] hybridized on the same microarrays:
rps19, cgi-119, ctbp1 and b2m.
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was regarded as significant whereas p-value <0.01 and
p-value <0.001 as highly significant.
Results
Selection of gene set used for diagnosis of malignant tumor
In the first analysis we built the classifier based on the
training data. The algorithm selected five genes: mipep,
serhl, relaxin, magi3 and zfp37 which expression canTable 2 Primers used for real-time qPCR








Primers sequences used in this study and their annealing optimal temperature and
Primers were designed using PRIMER3 software (free on-line access) and checked u
hprt and rps19 genes were used as non-regulated reference genes for normalizationallow us to diagnose the most malignant tumors. The
boosted tree rules were as follow:




of tarsehrl < = 4.046 [ Mode: 1 ] = > 1
sehrl > 4.046 [ Mode: 3 ] = > 3Rule 2. estimated accuracy 96.17% [boost 100%]
zfp37 < = 3.377 [ Mode: 1 ] = > 3
zfp37 > 3.377 [ Mode: 3 ] = > 1Rule 3. estimated accuracy 96.57% [boost 100%]
zfp37 < = 2.914 [ Mode: 1 ] = > 3
zfp37 > 2.914 [ Mode: 3 ] = > 1Rule 4. estimated accuracy 95.48% [boost 100%]
mipep < = 1.257 [ Mode: 1 ] = > 1
mipep > 1.257 [ Mode: 3 ] = > 3Rule 5. estimated accuracy 88.44% [boost 100%]
magi3 < = 1.458 [ Mode: 3 ] = > 3
magi3 > 1.458 [ Mode: 1 ] = > 1Rule 6. estimated accuracy 100% [boost 100%]
sehrl < = 4.046 [ Mode: 1 ]
relaxin1 < = 4.203 [ Mode: 1 ] = > 1
relaxin1 > 4.203 [ Mode: 3 ] = > 3
sehrl > 4.046 [ Mode: 3 ] = > 3Its efficacy assessed using the learning data was 100%
in case of the most malignant tumors.
Confirmation at mRNA level of the expression patterns of
`diagnostic` set of genes in canine mammary carcinomas
of various grade of malignancy
Real-Time qPCR analysis confirmed similar trends in
expression of the examined five genes (Figure 2). To
check the expression of the selected `gene set` in mam-
mary tumors in general, all the 18 tumors were under








he mRNA sequences of key genes were obtained from NCBI database.
ligo Calculator (free on-line access) and Primer-Blast (NCBI database).
get gene expression [6,7].
Figure 2 Expression of `diagnostic gene set` assessed using real-time qPCR. Expression of `diagnostic gene set` in canine mammary
carcinoma of various grade of malignancy. The changes in gene expression which differed significantly (p < 0.05) markered as *, the changes in
gene expression which differed highly significant (p < 0.01 and p < 0.001) markered as ** and ***, respectively.
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III (six of each group).
The highest relative expression of serhl showed grade
III tumors (0.0095 ± 9.75e-005), whereas the lowest ex-
pression showed grade I tumors (0.0044 ± 0.0002). The
relative mean expression of serhl in grade II tumors was
0.0057 (±0.0002). The relative expression of serhl dif-
fered highly significant between the most malignant tu-
mors and other groups (p < 0.01) (Figure 2A).
The highest relative expression of zfp37 showed grade
I tumors (0.0031 ± 0.0008), whereas the lowest expres-
sion exposed the most malignant tumors (0.0012 ± 5.5e-
005). The relative mean expression of zfp37 in grade II
tumors was 0.0022 (±0.0004). The relative expression of
zfp37 differed significantly between grade III tumors and
others (p < 0.05) (Figure 2B).
The highest relative expression of mipep presented
grade III tumors (0.025 ± 0.0044), whereas the lowest ex-
pression showed grade I tumors (0.009 ± 0.0005). The
relative mean expression of mipep in grade II tumors
was 0.015 (±0.0038). The relative expression of mipep
differed significantly between most malignant tumors
and others (p < 0.05) (Figure 2C).
The highest relative expression of relaxin gave us the
result grade III tumors (0.0019 ± 3.25e-005), whereas the
lowest expression showed grade I tumors (0.0006 ±
4.65e-005). The relative mean expression of relaxin ingrade II tumors was 0.0013 (±3.5e-005). The relative ex-
pression of relaxin differed highly significant between
grade I and grade III tumors (p < 0.001) and between
grade I and grade II tumors as well as grade II and grade
III tumors (p < 0.01) (Figure 2D).
The highest relative expression of magi3 showed grade
I tumors (0.0011 ± 0.0001), whereas the lowest expres-
sion was revealed in grade III tumors (0.0002 ± 5.5e-
006). The relative mean expression of magi3 in grade II
tumors was 0.0004 (±1.3e-005). The relative expression
of magi3 differed significantly between grade III tumors
and others (p < 0.001) (Figure 2E).
Expression of selected set of markers at protein level
Expression level of the proteins encoded by the `se-
lected gene set`: SERHL, ZFP37, MIPEP, relaxin and
MAGI3 was under examination by immunohistochem-
istry (Figure 3) in order to validate our previous find-
ings. We examined 60 tumors (20 of each grade of
malignancy). These tumors were classified by patholo-
gists as: grade I, grade II or grade III. They were simple
or complex carcinomas. No correlation between their
type and level of proteins expression had been found.
The antibodies (described in Materials and Methods
section) were dedicated to be used in various species, in-
dicating their wide cross-specificity. However, we have
performed the analysis of protein sequence in species
Figure 3 Expression of proteins encoded by `diagnostic gene set`. Pictures of SERHL, ZFP37, MIPEP, relaxin and MAGI3 in grade I, grade II
and grade III canine mammary carcinomas (n = 60) obtained using Olympus BX60 microscope (x200). The examined antigen is presented as a
brown precipitate. The colorimetric intensity of the IHC-stained antigen spots was counted by a computer-assisted image analyzer (Olympus
Microimage™ Image Analysis, software version 4.0 for Windows, USA) and the antigen spot color intensity is expressed as mean pixel optical
density on a 1–256 scale (data presented in Table 3).
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canine by blasting them using NCBI tool. Additionally,
we used the BLOSUM62 amino acid substitution matrix
to score alignments between evolutionarily divergent
protein sequences. Our results revealed a high similarity
between these proteins in dogs and reactivity species,
and thus based on the results we came up to use these
antibodies in our experiments. The analysis of whole
MAGI3 protein sequence showed 100% identity (protein
accession numbers: Q9JK71 and J9P535), 94% identity
in MIPEP (protein accession numbers: Q99797 and
F1PWG7), 80% identity in ZFP37 (protein accession
numbers: Q9Y6Q3 and J9P9T4), 64% identity in SERHL
(protein accession numbers: Q9EPB5) and 41% identity
in relaxin (protein accession numbers: P04808 and
Q9TRM8). The identity of the epitope recognized by
the antibodies or the peptide fragment used for
immunization in the antibody`s manufacturing processwas significant. We used similar approach in our previ-
ously published study [11].
We observed significantly (p < 0.01) increased expres-
sion of SERHL, MIPEP and relaxin in the grade III tu-
mors comparing to the other tumors. SERHL expression
in grade III tumors was 126.4 (±2.84), whereas in grade
II and grade I tumors 107.8 (±4.10) and 109.2 (±2.99),
respectively. MIPEP expression in grade III tumors was
123.5 (±3.88), whereas in grade II and grade I tumors it
came up as 118.4 (±3.77) and 100.1 (±4.72), respectively.
Expression of relaxin in grade III tumors was 125.2
(±1.08), whereas in grade II and grade I tumors it was
108.3 (±2.09) and 116.4 (±2.53). MIPEP expression was
also significantly increased (p < 0.05) in grade II tumors
comparing to the grade I. We also showed significantly
(p < 0.05) and highly significant (p < 0.001) decreased ex-
pression of MAGI3 and ZFP37 (respectively) in the most
malignant tumors (Table 3). Expression of MAGI3 in
Table 3 Optical density related with the expression of
examined proteins in canine mammary carcinoma at
various grade of malignancy
Antigen Grade I tumors Grade II tumors Grade III tumors
SERHL 109.2 (±2.99) 107.8 (±4.10) 126.4 (±2.84)**
ZFP37 124.2 (±1.46) 122.8 (2.70) 103.6 (3.13)***
MIPEP 100.1 (±4.72) 118.4 (±3.77)* 123.5 (±3.88)**
RELAXIN 116.4 (±2.53) 108.3 (2.09) 125.2 (1.08)**
MAGI3 124.2 (±0.69) 122.0 (±1.28) 103.0 (±1.87) *
The mean optical density of (±SD) related with expression of examined
antigens assessed in Microimage software (Olympus). Mean values were
calculated for 20 tumors of each pathological malignancy. For statistical
purposes, the ANOVA + Tukey post-hoc tests were applied (Graph Pad Prism
5.0). The values that differed significantly (p < 0.05) markered as *, whereas the
values that differed highly significant (p < 0.01 and p < 0.001) markered as **
and ***, respectively.
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II or grade I tumors it turned out to be 122.0 (±1.28)
and 124.2 (±0.69). Expression of ZFP37 in grade III tu-
mors was 103.6 (±3.13) whereas in grade II and grade I
it was 122.8 (±2.70) and 124.2 (±1.46), respectively.
The mean optical density of the brown precipitates re-
lated to the examined antigen expression was showed in
Table 3.
Discussion
Analysis of gene expression profiles of canine mammary
carcinoma of various grade of malignancy (n = 18)
followed by the boosted tree analysis distinguished a
`gene set` that might be helpful in diagnosis of canine
mammary malignancy. This `set` consisted of five genes
which expression have significantly changed in the most
malignant tumors: sehrl, zfp37, mipep, relaxin, and
magi3. Thus, based on their expression pattern the path-
ologist could distinguish between grade III tumors as
well as others. In case of canine mammary tumors, the
proper diagnosis is very important because it constitutes
basis to the prognosis. The increased histological grade
of malignancy is associated with an increased risk of
death within 2 years after mastectomy [4]. Despite the
proposed `gene set` seems to be useful in malignancy
diagnosis, its usefulness should be validated with higher
number of samples. So far, these genes and their prod-
ucts have not been treated as `malignancy markers` in
breast cancer. Due to similar epidemiological and clin-
ical characteristics of such tumors in these both species,
similar environmental conditions, epithelial nature of
these tumors, and similar composition of tumor micro-
environment, the use of canine mammary tumors as an
experimental model for human breast cancers is relevant
[11]. Thus, in our opinion these results could be
assessed in humans in order to validate the influence of
these genes on cancer malignant transformation. So far,
only two of these five genes were linked to cancer. Thesegenes have not yet been described as malignancy
markers in humans. In our opinion this `gene set` could
be also a interesting target for further investigation.
An increased expression of SERHL was observed dur-
ing passive stretch of skeletal muscles. It is suggested
that its up-regulation can be related with skeletal
muscle growth in response to mechanical stimuli [12].
Similar conditions (stretching and mechanical stimuli)
are observed in fast growing tumors. As being recognized
the most malignant tumors are significantly larger than
less malignant or benign tumors [13], increased expression
of SEHRL in the grade III tumors is not surprising
(Figure 2, Figure 3, Table 3).
The protein encoded by zfp37 belongs to the huge
family of zinc finger proteins, which are regulators of
transcription. High ZFP37 expression was shown during
neurons and chondrocyte development, however in
adults it was detected only in brain and testes [14,15].
ZFP37 is supposed to take part in development and dif-
ferentiation of the cell. The results of the presented
study showed significantly decreased expression of
this gene and its protein in the most malignant tumors
(Figure 2, Figure 3, Table 3). It can indicate the role of
ZFP37 in cancer differentiation due to decrease in differ-
entiation during the malignant transformation process in
cancer [16].
The other selected gene is mipep which is involved in
cellular metabolism. The product of this gene performs
the final step in processing of nuclear-encoded proteins
targeted to the mitochondrial matrix or inner membrane
[17]. This gene may contribute to the functional effects
of frataxin deficiency and the clinical manifestations of
Friedreich ataxia (FA). The exact function of frataxin is
still unclear, however it has been implicated in iron
homeostasis, protection from oxidative stress and apop-
tosis [18]. Conflicting results have been reported regard-
ing the role of frataxin in cellular growth: both frataxin
knockdown and frataxin over-expression impair cell
growth. Despite the role of frataxin in cancer is un-
known, the relation between FA and malignancy has
been suggested [19].
The next gene which increased expression was charac-
teristic for the most malignant canine mammary tumors
was relaxin. This peptide hormone, which is known as
an inhibitor of uterine contractility and promoter of
lengthen of the interpubic ligament before partition [20],
promotes growth and development of mammary gland
[21,22]. Moreover, it increases expression and catalytic
activities of matrix metalloproteinase (MMP) [20]. It has
been also found to enhance invasiveness of cancer cells
by MMPs modulation [20]. The results of the present
study showed up-regulation of relaxin in the most malig-
nant tumors (Figure 2, Figure 3, Table 3) which are usu-
ally the most invasive [23].
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nancy is magi3. The MAGI protein is usually detected in
the tight junctions between cells [24]. This protein reacts
with LPA2 receptors which expression is increased in tu-
mors and during inflammation [25,26], but inflammation
often accompanies cancer development [27,28]. More-
over, in normal cells the activation of this receptor is not
required [29]. LPA2 can be activated by MAGI3 or
NHERF-2. Knockdown of MAGI3 increases expression
of NHERF-2, which enhances cell growth, COX-2 ex-
pression and ensures cancer resistance to chemotherapy
[30,31]. These data correlates with our own findings that
MAGI3 expression was significantly down regulated in
the most malignant tumors (Figure 2, Figure 3, Table 3).
A group of Prof. Klopfleisch published a very interest-
ing paper exposing presentation of changes in proteome
at different stages of canine mammary cancer progres-
sion [32]. They found 48 proteins which expression sig-
nificantly changed between benign and malignant
tumors. These proteins do not overlap with our findings.
Differences may be related with the fact that a group of
Prof. Klopfleisch examined general differences between
benign and malignant tumors, whereas we have analyzed
specific differences between various grades of canine
mammary malignancy. However, both studies showed
that tumor progression is associated with a stepwise
change in protein expression levels, not only between
benign and malignant tumors, but also in a relation be-
tween less and more malignant ones.
Conclusions
The genes given above can altogether constitute a `set of
malignancy markers` used to distinguish the most malig-
nant canine mammary carcinomas from the others.
These genes are also interesting as targets for further in-
vestigations and therapy. So far, only two of them were
linked with the cancer development.
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